Das Ubiquitin-Proteasom-System und seine Bedeutung in der Onkologie

Schlüsselwörter

Ubiquitin-Proteasom-System - proteasomale Inhibition - Ubiquitinligasen - Deubiquitylasen - Multiples Myelom

Keywords

ubiquitin proteasome system - proteasomal inhibition - ubiquitin ligases - deubiquitylases - multiple myeloma

• Literatur

• 1 Bassermann F, Frescas D, Guardavaccaro D et al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008; 134: 256-267
• 2 Bassermann F, Pagano M. Dissecting the role of ubiquitylation in the DNA damage response checkpoint in G2. Cell Death Differ 2010; 17: 78-85
• 3 Bassermann F, von Klitzing C, Munch S et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 2005; 122: 45-57
• 4 Busino L, Millman SE, Scotto L et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012; 14: 375-385
• 5 Caligiuri MA, Briesewitz R, Yu J et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007; 110: 1022-1024
• 6 Dehan E, Bassermann F, Guardavaccaro D et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 2009; 33: 109-116
• 7 Dey A, Seshasayee D, Noubade R et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012; 337: 1541-1546
• 8 Fernández-Sáiz V, Targosz BS, Lemeer S et al. SCF(Fbxo9) and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol 2013; 15: 72-81
• 9 Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449
• 10 Haupt Y, Maya R, Kazaz A et al. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299
• 11 Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British journal of haematology 2004; 127: 165-172
• 12 Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-1575
• 13 Lamm W, Kaufmann H, Raderer M et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96: 1008-1014
• 14 Li M, Brooks CL, Kon N et al. A dynamic role of HAUSP in the p53-Mdm2 pathway. Molecular cell 2004; 13: 879-886
• 15 Li M, Chen D, Shiloh A et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002; 416: 648-653
• 16 Ludwig H, Beksac M, Blade J et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15: 6-25
• 17 Masuya D, Huang C, Liu D et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol 2006; 208: 724-732
• 18 Nakayama K, Nagahama H, Minamishima YA et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6: 661-672
• 19 Obeng EA, Carlson LM, Gutman DM et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916
• 20 Ohta T, Fukuda M. Ubiquitin and breast cancer. Oncogene 2004; 23: 2079-2088
• 21 Oliner JD, Kinzler KW, Meltzer PS et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83
• 22 Popov N, Wanzel M, Madiredjo M et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774
• 23 Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England journal of medicine 2005; 352: 2487-2498
• 24 Sanada M, Suzuki T, Shih LY et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904-908
• 25 Sargin B, Choudhary C, Crosetto N et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007; 110: 1004-1012
• 26 Scheffner M, Huibregtse JM, Vierstra RD et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505
• 27 Schwickart M, Huang X, Lill JR et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107
• 28 Soucy TA, Smith PG, Milhollen MA et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736
• 29 Strohmaier H, Spruck CH, Kaiser P et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413: 316-322
• 30 Su Y, Fu C, Ishikawa S et al. APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol Cell 2008; 32: 652-661
• 31 Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848
• 32 Wang Q, Moyret-Lalle C, Couzon F et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 2003; 22: 1486-1490
• 33 Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature reviews Cancer 2008; 8: 83-93
• 34 Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434
• 35 Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 2004; 23: 2096-2106
• 36 Zhang C, Cai TY, Zhu H et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 2011; 10: 1264-1275